Eurocine Vaccines has received notice of allowance for a US patent application
Eurocine Vaccines has received notice of allowance in the US for one of its patent applications. The patent application, involving the company´s nasal influenza vaccine candidate Immunose™ FLU, has been examined and is allowed for issuance as a patent.
“We are pleased that one of our applications has been allowed by the U.S. Patent Office and we are encouraged to continue our systematic work to protect our rights”, said CSO Dr. Anna-Karin Maltais.
“This notice of allowance, in the world´s biggest pharmaceutical market, strengthens us in our discussions with potential partners and in our further development of Immunose™ FLU“, said CEO Dr. Hans Arwidsson.
This information is information that Eurocine Vaccines AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 24th 2017.
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
Eurocine Vaccines is a publicly listed company, using its clinically validated and patented technology Endocine™ initially to develop a nasal influenza vaccine for children. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza. The company´s main project, the nasal quadrivalent influenza vaccine candidate Immunose™ FLU, is in clinical phase I/II development during the influenza season 2016/2017. Good safety has been reported and a report on the immune responses from the study is expected June/July 2017.
The company plans to license the product to partners for further development and commercialization.
Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.
Tags: